人參皂苷 Rh1作用機(jī)制 - Medchemexpress - MCE中國(guó)

1、Product Data SheetGinsenoside Rh1Cat. No.: HY-N0604CAS No.: 63223-86-9分式: CHO分量: 638.87作靶點(diǎn): PPAR; TNF Receptor; Interleukin Related; Endogenous Metabolite作通路: Cell Cycle/DNA Damage; Apoptosis; Immunology/Inflammation; MetabolicEnzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months

2、-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 100 mg/mL (156.53 mM; Need ultrasonic)SolventMass1 mg 5 mg 10 mgConcentration制備儲(chǔ)備液1 mM 1.5653 mL 7.8263 mL 15.6526 mL5 mM 0.3131 mL 1.5653 mL 3.1305 mL10 mM 0.1565 mL 0.7826 mL 1.5653 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存式和期限：-80C, 6 months; -20C

3、, 1 month。-80C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?6 個(gè)內(nèi)使，-20C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?1 個(gè)內(nèi)使。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?。以下溶解案都?qǐng)先按照 In Vitro 式配制澄清的儲(chǔ)備液，再依次添加助溶劑：為保證實(shí)驗(yàn)結(jié)果的可靠性，澄 的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL

4、(3.91 mM); Clear solution此案可獲得 2.5 mg/mL (3.91 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲(chǔ)備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (3.91 mM); Clear solutionPage 1 of 2 www.MedChemE此案可獲

5、得 2.5 mg/mL (3.91 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲(chǔ)備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合均勻。3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (3.91 mM); Clear solution此案可獲得 2.5 mg/mL (3.91 mM，飽和度未知) 的澄 溶液，此案不適于實(shí)驗(yàn)周 期在半個(gè)以上的實(shí)驗(yàn)。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲(chǔ)備液加到 900 L 油

6、中，混合均勻。BIOLOGICAL ACTIVITY物活性 Ginsenoside Rh1 (Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1)是從 Panax Ginseng 根部分離的。Ginsenoside Rh1 抑制 PPAR-，TNF-，IL-6 和 IL-1 的表達(dá)。IC & Target PPAR- IL-6 IL-1 TNF-Human EndogenousMetabolite(批量添加)體外研究 The effect of Ginsenoside Rh1 is examined on adipogenesis in 3T3

7、-L1 cells. Ginsenoside Rh1 potently inhibits theadipogenesis, as assessed by Oil-red O staining and lipid contents in 3T3-L1 adipocytes. Ginsenoside Rh1, atconcentrations of 50 M and 100 M, inhibit the adipogenesis by 50% and 63%, respectively.The expression levels ofadipocytespecific genes such as

8、PPAR-, C/EBP-, FAS, aFABP and some genes are examined during early phase ofdifferentiation such as Pref-1, C/EBP- and Glucocorticoid receptor (GR). After the treatment with Ginsenoside Rh1 in3T3-L1 cells, mRNA is extracted on 18 h and 24 h for Pref-1, C/EBP- and GR and day 8 for PPAR-, C/EBP-, FAS,a

9、FABP. Then, the expression profiles of adipocyte-specific genes are investigated by RT-PCR. PPAR-, C/EBP-, FAS,and aFABP expressions are significantly increased in DMI-stimulated differentiated adipocyte compared to those ofnon-stimulated adipocyte cells. However, treatment with DMI in the presence

10、of Ginsenoside Rh1 significantlysuppresses the expression levels of PPAR-, C/EBP-, FAS, and aFABP in a dose- dependent manner, whereas theexpression levels of Pref-1, C/EBP- and GR are not affected1.體內(nèi)研究 When high-fat diet (HFD) fed mice for 8 weeks, body and epididymal fat weight gains are signific

11、antly increasedcompared to those of low-fat diet (LFD)-fed mice. However, when Ginsenoside Rh1 is treated in HFD-fed mice, bodyand epididymal fat weight gains are significantly decrease compared with those of the HFD-fed mice. TG, glucose,insulin, total cholesterol, and HDL levels in the blood are s

12、ignificantly increased in HFD-fed mice group compared toLFD-fed mice group. Treatment with Ginsenoside Rh1 in HFD-fed mice significantly lowers TG level alone1.PROTOCOLCell Assay 1 Mouse embryo fibroblasts 3T3-L1 cells are incubated in DMEM, containing 10% FBS and 1% AB, at 37C and 5.6%CO2 atmospher

13、e. To induce differentiation, two days after confluence, preadipocytes (designated day 0) are culturedin the differentiation medium (DM), which is consisted of DMEM, 10% FBS, 1% AB, and DMI (0.28 unit/mL insulin, 0.5mM Isobutylmethylxanthine and 1 M Dexamethasone) for 2 d in the presence or absence

14、of 50 M and 100 M ofGinsenoside Rh1, and switched to DM containing 10% FBS and 10 g/mL insulin and then changed to DMEMmedium with 10% FBS for every 2 d1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Page 2 of 3 www.MedChemEAnimal Mice1Administration

15、1 Male C57BL/6J mice are separated into 3 groups, LFD, HFD and HFDRh1. Each group is consisted of ten mice. LFDgroup fed LFD for 8 weeks. HFD group fed HFD for 8 weeks. HFDRh1 group fed HFD diet for 4 weeks and thensimultaneously treated with HFD and 20 mg/kg/d Ginsenoside Rh1, which is orally admin

16、istrated. Weight and foodintake of mice are measured daily. After finishing treatment for 4 weeks, blood and epididymal fats are collected forfurther analysis.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Gu W, et al. Ginsenoside Rh1 ameliorates high fat diet-induced obesity in mice by inhibiting adipocyte differentiation. Biol Pharm